ArticleHaematologica2020

Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.

Juliana Velez Lujan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.